TMS Impact on Cognitive Sequencing
Trial Summary
What is the purpose of this trial?
Although there is increasing recognition that the cerebellum is involved in cognition as well as motor function, the manner in which the cerebellum contributes to cognition is uncertain. One theory that might account for both motor and cognitive contributions of the cerebellum is that the cerebellum is involved in sequencing of relevant events or stimuli. Previous experiments have suggested that disruption of the cerebellum impairs the prediction of the next event in a sequence. The present experiment will examine the impact of cerebellar stimulation on brain activation during the performance of both sequence-demanding and non-sequence-demanding tasks.
Will I have to stop taking my current medications?
Yes, you will need to stop taking anxiolytic, antidepressant, neuroleptic, or sedative medications to participate in this trial.
What data supports the effectiveness of the treatment TMS Impact on Cognitive Sequencing?
Research shows that repetitive transcranial magnetic stimulation (rTMS) can influence cognitive tasks, such as improving working memory and modulating sequence learning, by targeting specific brain areas like the dorsolateral prefrontal cortex. This suggests that rTMS might be effective in enhancing cognitive sequencing by altering brain activity in targeted regions.12345
Is transcranial magnetic stimulation (TMS) generally safe for humans?
Transcranial magnetic stimulation (TMS) is generally considered safe, but it can cause seizures in rare cases and may have temporary effects on brain function. Most studies suggest that serious problems are unlikely, but further research is needed to fully understand all potential side effects.678910
How does the TMS treatment for cognitive sequencing differ from other treatments?
This TMS treatment is unique because it uses non-invasive brain stimulation to specifically target cognitive sequencing tasks, allowing researchers to explore causal brain-behavior relationships and the timing of neural processes, unlike traditional treatments that may not provide such precise control over brain activity.13111213
Research Team
John E Desmond, Ph.D.
Principal Investigator
Johns Hopkins University
Eligibility Criteria
This trial is for individuals aged 18-50 who can consent, have at least an 8-year education, speak English fluently, and are right-handed. It's not for those with recent drug use, cognitive impairments due to neurological disorders, psychiatric disorders including substance abuse, stroke history, MRI contraindications or visual deficits.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo TMS stimulation during sequence-demanding and non-sequence-demanding tasks, with brain activation measured via fMRI
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- No TMS during non-sequence-demanding task
- No TMS during sequence-demanding task
- TMS during non-sequence-demanding task
- TMS during sequence-demanding task
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
National Institute of Mental Health (NIMH)
Collaborator